Treatment of Epilepsy with Eyelid Myoclonia in Women of Childbearing Age
This protocol covers first-line antiseizure management for patients diagnosed with epilepsy with eyelid myoclonia who are female and of childbearing age — a population for which treatment selection follows a distinct, evidence-based pathway.
Clinical Scenario
The protocol applies to women of reproductive age. This specific population is central to treatment decision-making, and the choice of antiseizure agent in this group is guided by strong consensus recommendations.
Treatment Approach
Evidence-based first-line options are available for this syndrome in this population. Equally important is the recognition that certain medication classes are contraindicated — they risk worsening the syndrome rather than controlling it. The full protocol specifies which agents are appropriate and which must be avoided, along with the clinical rationale.
Treatment Goals
Acceptable seizure control in this syndrome includes eyelid myoclonia without absence seizures or altered awareness, provided that other seizure types remain controlled.
References
DOI: 10.1111/epi.17682
- There was also a strong consensus that levetiracetam (21/25, 84%) or lamotrigine (21/25, 84%) are reasonable first‑line options for women of childbearing age.
- There was a strong consensus (21/24, 88%) that sodium channel‑blocking medications, except for lamotrigine, should not be used, as they may exacerbate the syndrome.
- There was a strong consensus among physician panelists (21/25, 84%) and agreement among patients/caregivers (3/4, 75%) that the goals of treatment include accepting eyelid myoclonia without absence seizures or altered awareness, provided other seizures are controlled.